Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 838

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 838
---
                 | ​ |    408 | ​ | ​ |
| Restricted cash, long-term assets                                                                    | ​ | ​ | ​                 | ​ |  1,500 | ​ | ​ | ​ | ​                 | ​ |      — | ​ | ​ |
| Total cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows | ​ | ​ | ​                 | $ | 53,683 | ​ | ​ | ​ | ​                 | $ | 64,149 | ​ | ​ |

F-59

TABLE OF CONTENTS

CARA THERAPEUTICS, INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(amounts in thousands, except share and per share data) 9. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consist of the following:

| ​                                   | ​ | ​ | December 31, 2023 |   |        |   | ​ | ​ | December 31, 2022 |   |        |   | ​ |
|:------------------------------------|:--|:--|:------------------|:--|-------:|:--|:--|:--|:------------------|:--|-------:|:--|:--|
| Accounts payable                    | ​ | ​ | ​                 | $ | 11,583 | ​ | ​ | ​ | ​                 | $ |  9,604 | ​ | ​ |
| Accrued research projects           | ​ | ​ | ​                 | ​ |  4,343 | ​ | ​ | ​ | ​                 | ​ |  5,200 | ​ | ​ |
| Accrued compensation and benefits   | ​ | ​ | ​                 | ​ |  6,519 | ​ | ​ | ​ | ​                 | ​ |  5,219 | ​ | ​ |
| Accrued professional fees and other | ​ | ​ | ​                 | ​ |  3,147 | ​ | ​ | ​ | ​                 | ​ |  1,517 | ​ | ​ |
| Total                               | ​ | ​ | ​                 | $ | 25,592 | ​ | ​ | ​ | ​                 | $ | 21,540 | ​ | ​ |

10. Royalty Purchase and Sale Agreement During the fourth quarter of 2023, the Company, through its wholly-owned subsidiary Cara Royalty Sub, LLC, a Delaware limited liability company, or Cara